

# **Review of TA407; Secukinumab for active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors**

## **Decision**

The guidance remains relevant and an update is not needed.

## **Background**

TA407 was published in September 2016 (see appendix A) and scheduled to be considered for review in 2019.

Stakeholders were asked whether the guidance is still relevant and whether there is new evidence that would affect the recommendations (see appendix B).

Based on the information received, we found nothing new that affects the existing recommendations. The guidance remains relevant and an update is not needed. This may change if NICE becomes aware of new evidence that would make it reconsider.

## **Decision paper sign off**

Jennifer Prescott – Programme Director, Planning and Operations

20 May 2020

## **Contributors to this paper**

Project Manager: Charlotte Downing

## **Appendix A – Information from existing guidance**

### **Original remit**

To appraise the clinical and cost effectiveness of secukinumab within its marketing authorisation for treating ankylosing spondylitis after inadequate response to non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors.

### **Current guidance**

1.1 Secukinumab is recommended, within its marketing authorisation, as an option for treating active ankylosing spondylitis in adults whose disease has responded inadequately to conventional therapy (non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors). The drug is recommended only if the company provides it with the discount agreed in the patient access scheme.

1.2 Assess the response to secukinumab after 16 weeks of treatment and only continue if there is clear evidence of response, defined as:

- a reduction in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score to 50% of the pre-treatment value or by 2 or more units and
- a reduction in the spinal pain visual analogue scale (VAS) by 2 cm or more.

1.3 When using BASDAI and spinal pain VAS scores, healthcare professionals should take into account any physical, sensory or learning disabilities, or communication difficulties that could affect the responses to the questionnaires, and make any adjustments they consider appropriate.

## Appendix B – Stakeholders asked to comment

### Stakeholders who agree that the guidance should remain unchanged

- AbbVie Ltd
- British Society for Rheumatology (BSR)
- MSD
- Novartis Pharmaceuticals UK Ltd
- Pfizer Ltd

### No response received from

- Action on Pain
- Allied Health Professionals Federation
- Arthritis & Musculoskeletal Alliance (ARMA)
- Arthritis Action
- Association of Surgeons of Great Britain and Ireland
- Back Care
- Black Health Agency
- Board of Community Health Councils in Wales
- Bone Research Society
- British Geriatrics Society
- British Institute of Musculoskeletal Medicine
- British National Formulary
- British Orthopaedic Association
- British Pain Society
- British Society of Paediatric and Adolescent Rheumatology
- British Society of Rehabilitation Medicine
- Care Quality Commission
- Chartered Society of Physiotherapy
- Chronic Pain Policy Coalition
- Cochrane Musculoskeletal Group

- College of Occupational Therapists
- Department of Health and Social Care
- Department of Health, Social Services and Public Safety for Northern Ireland
- Disability Rights UK
- Healthcare Improvement Scotland
- Hospira (infliximab)
- Leonard Cheshire Disability
- Medicines and Healthcare Products Regulatory Agency
- MRC Clinical Trials Unit
- Muslim Council of Britain
- Napp Pharmaceuticals / Celltrion Healthcare (infliximab)
- National Ankylosing Spondylitis Society
- National Association of Primary Care
- National Institute for Health Research
- National Pharmacy Association
- NHS Alliance
- NHS Central Manchester CCG
- NHS Confederation
- NHS England
- NHS Leeds West CCG
- Pain Concern
- Pain Relief Foundation
- Pain UK
- Physiotherapy Pain Association
- Primary Care Rheumatology Society
- Public Health England
- Public Health Wales
- Royal College of General Practitioners
- Royal College of Nursing
- Royal College of Pathologists
- Royal College of Physicians
- Royal College of Surgeons

- Royal Pharmaceutical Society
- Royal Society of Medicine
- Scottish Medicines Consortium
- Society for Back Pain Research
- South Asian Health Foundation
- Specialised Healthcare Alliance
- UCB Pharma (certolizumab pegol)
- UK Clinical Pharmacy Association
- Verses Arthritis
- Welsh Government